key: cord-0891417-fwc5wjiu authors: Gilbert, Richard E.; Caldwell, Lauren; Misra, Paraish S.; Chan, Kin; Burns, Kevin D.; Wrana, Jeffrey L.; Yuen, Darren A. title: Overexpression of the SARS-CoV-2 receptor, ACE-2, in diabetic kidney disease: implications for kidney injury in Covid-19 date: 2020-07-18 journal: Can J Diabetes DOI: 10.1016/j.jcjd.2020.07.003 sha: 158af23edb4da71ad0a13baa3e03d7c015195b45 doc_id: 891417 cord_uid: fwc5wjiu Abstract Objective Diabetes is associated with adverse outcomes including death following Covid-19 infection. Beyond the lungs, SARS-CoV-2, the aetiological agent of the Covid-19 pandemic, can infect a range of other tissues including the kidney, potentially contributing to the acute kidney injury in those with severe disease. We hypothesised that the renal abundance of ACE2, the cell surface receptor for SARS-CoV-2, may be modulated by diabetes and agents that block the renin-angiotensin-aldosterone system (RAAS). Methods The expression of ACE2 was examined in 49 archival kidney biopsies from patients with diabetic kidney disease and from 12 healthy, potential living allograft donors using next generation sequencing technology (RNA Seq). Results Mean ACE2 mRNA was increased approximately two-fold in diabetes when compared with healthy controls (13.2 ± 7.9 versus 7.7 ± 3.6 reads per million reads [RPM]; mean ± SD; diabetic versus controls; p = 0.001). No difference in transcript abundance was noted between recipients and non-recipients of agents that block the renin-angiotensin-aldosterone system (12.2 ± 6.7 versus 16.2 ± 10.7 RPM; RAAS recipients versus non-recipients; p=0.25). Conclusions Increased ACE2 mRNA in the diabetic kidney may increase the risk and/or severity of kidney infection with SARS-CoV-2 in the setting of Covid-19 disease. Further studies are needed to ascertain whether this diabetes-related overexpression is generalizable to other tissues, most notably the lungs. Diabetes is associated with an adverse outcome including death following Covid-19 infection 1 , though whether it may also increase susceptibility to infection is unknown. SARS-CoV-2, the etiological agent of the pandemic, binds to the cell surface ectoenzyme, angiotensin-converting enzyme 2 (ACE2), the abundance of which may be a determinant of virus entry and vulnerability to infection 2 . Recent studies have identified the kidney as a site of infection by SARS-CoV-2 3 , and have highlighted acute kidney injury as a common adverse outcome in patients with severe Covid-19 disease 4 . And while hemodynamic imbalance and cytokine release are likely contributors to the acute loss of kidney function, the ability of the SARS-CoV-2 to infect kidney cells and to induce immunological injury and microthrombus formation 5 suggest that the virus itself may be directly involved 6 . Substantial advances have been made in the assessment of gene expression in kidney biopsies, focussing, in particular, on site-specific changes in glomeruli and to a lesser extent tubules 7 . ACE2, however, is highly expressed in macrophages 8 and in the microvasculature 9 that reside in the interstitial space and traditionally not subjected to selective laser capture microscopic microdisscetion of the kidney 7 . Accordingly, we sought to examine the abundance of ACE2 in whole rather than microdissected biopsy tissue from individuals with diabetic kidney disease. To assess the transcriptome in these biopsies, ten, 10 µm thick sections were cut from formalin fixed paraffin-embedded (FFPE) kidney biopsy blocks or from fresh frozen (FF) tissue embedded in cryomatrix. Total RNA was extracted, ribosomal RNA (rRNA) was removed, and cDNA libraries were then prepared and quantitated prior to RNA sequencing (Illumina HiSeq 3000), as previously reported 10 . Abundance of ACE2 possibility that such individuals may be at higher risk of kidney infection with SARS-CoV-2 in Covid-19 disease, potentially increasing the risk of AKI and death. The study, further, provides reassurance that any propensity to infection should not be exacerbated by concomitant use of agents that block the RAAS. The main strengths of this study are the number of biopsies examined, the state-of-theart technology used to quantify gene expression and the documentation of medications taken at the time of biopsy. We found only a single published study that compared ACE2 mRNA in kidney biopsies from patients with diabetes with that of healthy controls using robust methodology (quantitative PCR) 7 . In contrast to the current study of 49 biopsies, the number of biopsies in the study by Reich was comparatively small, examining only 13 biopsies from diabetic patients and showing a reduction in expression in diabetes. Moreover, unlike our study, the use of laser capture of proximal tubules and glomeruli in the latter study would not have fully taken into account the abundant ACE2 expression in infiltrating cells, the postglomerular vasculature, and nephron segments beyond the proximal tubule that may display differential expression in diabetes 11 . Indeed, macrophages and pericytes have been shown to express high levels of ACE2 suggesting that these cells may be particularly vulnerable to SARS-CoV-2 infection 8 . In addition, the use of next generation RNA seq technology enabled a true measurement of ACE2 transcript levels, as opposed to the relative levels generated by semi-quantitative PCR or microarray-based techniques. Finally, archived remnants of formalin-fixed paraffin-embedded core biopsies have not generally been used for RNA seq, as the yield and quality of RNA from such small tissue samples has been insufficient for RNA sequencing. Our technology, developed in bladder tumours 10 , overcame these limitations, enabling us to examine ACE2 expression in small, residual amounts of clinically indicated renal biopsy samples. In spite of the large number of biopsy specimens studied and reliance on whole rather than microdissected tissue, our study does, however, have several limitations. Most notably, the study was confined to the examination of kidney tissue and not lungs, the principal site of Covid-19 infection. Moreover, having studied only patients with biopsyproven diabetic kidney disease, we are unable to make any inferences on whether the changes in ACE2 mRNA observed in the current study apply to other organs, most notably the lungs, or if the changes in ACE2 expression seen in our study group also applies to the kidneys of individuals with diabetes and normal kidney function. In addition, the current study which assessed gene expression in sections cut from kidney biopsies was unable to determine cell-specific patterns of expression that may have differentially affected parenchymal, vascular, and inflammatory cells. Finally, while the abundance of a receptor required for SARS-CoV-2 entry was examined, many more components of the cell machinery are required for the virus to infect a cell, initiate virus replication and kill its host and while we assessed gene expression, its translation into protein was not examined. Diabetes is a well-known risk factor not only for severe bacterial infections but also for viral infections such as H1N1 influenza 12 . As was the case in previous human coronavirus infections such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), individuals with diabetes are also at higher risk of adverse outcomes with Covid-19 13 . While this may reflect a generalised predisposition to poor outcome with infectious diseases, it may also be a consequence of an increased propensity for cellular entry and invasion by SARS-CoV-2, though noting that the current study assessed ACE2 gene expression in the kidney and not in the lungs. For instance, studies of a related murine coronavirus showed a dose-dependent relationship between the number of infective virus particles and the likelihood of death 14 . Tissue-specific viral receptor abundance may also influence infectivity 11 and thereby contribute to the extrapulmonary manifestations of Covid-19 such as kidney and vascular disease. Consistent with this clinical observation, single cell RNA sequencing (scRNA-Seq) identified cells in the lung, kidney and heart as major sites of ACE2 expression 2 . Accordingly, the augmented kidney ACE2 expression demonstrated in the present study may signify a greater propensity to renal complications of Covid-19 among individuals with diabetes. A number of recently published observational studies concluded that the use of agents that block the RAAS increased neither the propensity to infection nor the likelihood of an adverse outcome [15] [16] [17] . While these studies did not specifically examine whether this broad conclusion also applied to individuals with diabetes, the current study does not indicate any relationship between the use of agents that block the RAAS and ACE2 expression in the diabetic setting. REG reports receiving research grants to his institution from AstraZeneca and Boehringer Ingelheim; serving on advisory panels for AstraZeneca, Boehringer Ingelheim, and Janssen; receiving CME speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen, all unrelated to the current study. He also reports being a shareholder in Certa Therapeutics, OccuRx and Fibrocor Therapeutics and is CSO of Fibrocor Therapeutics. JLW and DAY are consultants and own shares in Fibrocor Diabetes is associated with an adverse outcome including death following Covid-19 infection 1 , though whether it may also increase susceptibility to infection is unknown. Substantial advances have been made in the assessment of gene expression in kidney biopsies, focussing, in particular, on site-specific changes in glomeruli and to a lesser extent tubules 7 . ACE2, however, is highly expressed in macrophages 8 and in the microvasculature 9 that reside in the interstitial space and traditionally not subjected to selective laser capture microscopic microdisscetion of the kidney 7 . Accordingly, we sought to examine the abundance of ACE2 in whole rather than microdissected biopsy tissue from individuals with diabetic kidney disease. To assess the transcriptome in these biopsies, ten, 10 µm thick sections were cut from formalin fixed paraffin-embedded (FFPE) kidney biopsy blocks or from fresh frozen (FF) tissue embedded in cryomatrix. Total RNA was extracted, ribosomal RNA (rRNA) was removed, and cDNA libraries were then prepared and quantitated prior to RNA At the time of biopsy, approximately three quarters (38 of 49) of those with diabetic kidney disease were receiving therapy with at least one agent that blocks the RAAS, 25 as single agent ACE inhibitor, ARB or MRA treatment with 11 prescribed dual therapy and a further two receiving triple ACE, ARB and MRA combination treatment ( Table 1) . As in most other sites, there were more men than women in the diabetic kidney disease group with the reverse pattern seen in the control, living allograft donors. The magnitude of ACE2 gene expression in biopsies obtained from patients with diabetic kidney disease varied widely when compared with that found in biopsies from healthy controls. The variability notwithstanding, mean ACE2 mRNA was increased approximately two-fold in diabetes when compared with healthy controls (Figure 1 , Supplemental Figure 2) . Similarly, we found no relationship between ACE2 copy number and either A1c (Spearman rho = 0.05; p = 0.8) or between ACE2 copy number and eGFR (rho = 0.10, p = 0.5). An increase in ACE2 expression in the setting of diabetic kidney disease raises the possibility that such individuals may be at higher risk of kidney infection with SARS- In spite of the large number of biopsy specimens studied and reliance on whole rather than microdissected tissue, our study does, however, have several limitations. Most notably, the study was confined to the examination of kidney tissue and not lungs, the principal site of Covid-19 infection. Moreover, having studied only patients with biopsyproven diabetic kidney disease, we are unable to make any inferences on whether the changes in ACE2 mRNA observed in the current study apply to other organs, most notably the lungs, or if the changes in ACE2 expression seen in our study group also applies to the kidneys of individuals with diabetes and normal kidney function. In addition, the current study which assessed gene expression in sections cut from kidney biopsies was unable to determine cell-specific patterns of expression that may have differentially affected parenchymal, vascular, and inflammatory cells. Finally, while the abundance of a receptor required for SARS-CoV-2 entry was examined, many more components of the cell machinery are required for the virus to infect a cell, initiate virus replication and kill its host and while we assessed gene expression, its translation into protein was not examined. Diabetes is a well-known risk factor not only for severe bacterial infections but also for viral infections such as H1N1 influenza 12 . As was the case in previous human coronavirus infections such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), individuals with diabetes are also at higher risk of adverse outcomes with Covid-19 13 . While this may reflect a generalised predisposition to poor outcome with infectious diseases, it may also be a consequence of an increased propensity for cellular entry and invasion by SARS-CoV-2, though noting that the current study assessed ACE2 gene expression in the kidney and not in the lungs. Interaction between a virus and its host cells are key determinants of infection severity. For instance, studies of a related murine coronavirus showed a dose-dependent relationship between the number of infective virus particles and the likelihood of death 14 . Tissue-specific viral receptor abundance may also influence infectivity 11 A number of recently published observational studies concluded that the use of agents that block the RAAS increased neither the propensity to infection nor the likelihood of an adverse outcome [15] [16] [17] . While these studies did not specifically examine whether this broad conclusion also applied to individuals with diabetes, the current study does not indicate any relationship between the use of agents that block the RAAS and ACE2 expression in the diabetic setting. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Kidney disease is associated with in-hospital death of patients with COVID-19 Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury Multiorgan and Renal Tropism of SARS-CoV-2 Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 ACE2 and AT4R are present in diseased human blood vessels Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis Diabetes and the severity of pandemic influenza A (H1N1) infection COVID-19 pandemic, coronaviruses, and diabetes mellitus Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2 Kidney disease is associated with in-hospital death of patients with COVID-19 Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury Multiorgan and Renal Tropism of SARS-CoV-2 Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 ACE2 and AT4R are present in diseased human blood vessels Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis Diabetes and the severity of pandemic influenza A (H1N1) infection COVID-19 pandemic, coronaviruses, and diabetes mellitus Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19 Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19 The authors would like to thank Niki Dacouris, Michelle Nash, Lindita Rapi, and Weiqiu Yuan for their assistance with patient data collection. The authors are grateful for the Boehringer Ingelheim; serving on advisory panels for AstraZeneca, Boehringer Ingelheim, and Janssen; receiving CME speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen, all unrelated to the current study. He also reports being a shareholder in Certa Therapeutics, OccuRx and Fibrocor Therapeutics and is CSO of Fibrocor Therapeutics. JLW and DAY are consultants and own shares in Fibrocor